ALVO OAKTREE ACQUISITION CORP II

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its corporate leadership team as Chief Quality Officer, effective October 14.  Ms. Tanksley succeeds Reem Malki, who is stepping down for personal reasons.

“Sarah has been actively working with Alvotech as a consultant and we are very pleased that she will join our team in this new capacity,” said Mark Levick, Chief Executive Officer of Alvotech. “Her familiarity with our operation facilitates a smooth transition and we are excited to benefit further from her experience in regulatory compliance and GMP.  Sarah brings strong capabilities to the role of Chief Quality Officer, having excelled in regulatory agency roles as well as a respected industry practitioner. I also want to thank Reem for her vital contribution to the Alvotech team, as we built a world-class biosimilars development and manufacturing platform and achieved successful market launches of our first biosimilar in both Europe and Canada.”

Ms. Tanksley has 20 years of experience within the U.S. National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and as an industry consultant. She teaches graduate courses in GMP compliance and Regulatory Affairs as an Adjunct Professor in the Graduate Biochemistry and Molecular Biology Program at Georgetown University School of Medicine and with the Advanced Academic Program at Johns Hopkins University. Sarah has an MS degree in Bioscience Regulatory Affairs from Johns Hopkins University, as well as an MS degree in Biochemistry and Molecular Biology from Georgetown University School of Medicine.

About Alvotech

Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit . None of the information on the Alvotech website shall be deemed part of this press release.

CONTACTS

Alvotech Investor Relations and Global Communication

Benedikt Stefansson



EN
11/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE

Alvotech’s Private Placement Completed with Delivery of SDRs and Share...

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based f...

 PRESS RELEASE

Öll bréf afhent kaupendum í hlutafjárútboði Alvotech

Öll bréf afhent kaupendum í hlutafjárútboði Alvotech Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að fyrirtækið afhent bréf til þátttakenda í lokuðu hlutafjárútboði sem fram fór þann 4. júní sl. Um 40 stofnanafjárfestar tóku þátt í útboðinu. Um 60% af heildareftirspurninni kom frá fjárfestum í Svíþjóð, Noregi og Bretlandi, um 30% frá sjóðum í Bandaríkjunum og um 10% frá Íslandi. Yfir 80% bréfanna voru keypt af fjárfestum sem eru nýir hluthafar í Alvotech. „Það er okkur ánægja að þessi stóri hópur nýrra hluthafa, sem hafa mikla reynslu af fjárfestingu í heilbrigðisfyrirtækjum og líftæk...

 PRESS RELEASE

Alvotech’s Private Placement Completed with Delivery of SDRs and Share...

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based f...

 PRESS RELEASE

Alvotech Participates in the Goldman Sachs Global Healthcare Conferenc...

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs 46th Global Healthcare Conference, which will be held in Miami, Florida June 9-11, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday June 11, 2025, at 8:00 am EDT (12:00 GMT / 14:00 CEST)...

 PRESS RELEASE

Alvotech tekur þátt í árlegri heilbrigðisráðstefnu Goldman Sachs fjárf...

Alvotech tekur þátt í árlegri heilbrigðisráðstefnu Goldman Sachs fjárfestingabankans í Miami Alvotech (NASDAQ: ALVO) tekur þátt í árlegri heilbrigðisráðstefnu Goldman Sachs fjárfestingabankans sem haldin verður í Miami dagana 9.-11. júní nk. Fulltrúar félagsins funda með einstökum fjárfestum og Dr. Balaji Prasad, framkvæmdastjóri stefnumótunar, situr fyrir svörum greinanda bankans og fjallar um nýjustu áfanga í starfsemi félagsins, miðvikudaginn 11. júní kl. 12:00 á hádegi. Hægt verður að hlusta útsendingu af kynningunni í beinu streymi. Þá verður upptaka aðgengileg á vefsíðu félagsins í 9...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch